Morgan Stanley Acurx Pharmaceuticals, Inc. Put Options Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ACXP
# of Institutions
30Shares Held
1.52MCall Options Held
13.6KPut Options Held
4K-
Vanguard Group Inc Valley Forge, PA529KShares$201,1520.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$139,2980.08% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$55,6700.0% of portfolio
-
Vanguard Capital Wealth Advisors67.5KShares$25,6500.03% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA48.4KShares$18,3820.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $4.39M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...